文献速递泌尿男性生殖肿瘤

比较卡巴他赛减量(20 mg/m2)与现行批准剂量(25 mg/m2)用于多西他赛治疗后转移性去势抵抗性前列腺癌患者的III期研究——PROSELICA

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
PubMed 文献 · J Clin Oncol · 2017-08-15

PROSELICA是一项III期随机研究,比较卡巴他赛20 mg/m2(C20)与25 mg/m2(C25)在多西他赛治疗后转移性去势抵抗性前列腺癌患者中的疗效。共1200例患者随机分组(C20组598例,C25组602例)。C20组中位总生存13.4个月,C25组14.5个月(HR 1.024),HR置信区间上限1.184未超过非劣效界值1.214,非劣效终点达成;C25组前列腺特异性抗原(PSA)缓解率和至PSA进展时间更优,C20组3/4级治疗中出现的不良事件发生率更低(39.7% vs 54.5%)。

要点

  • C20组中位总生存13.4个月,C25组14.5个月,HR 1.024,HR置信区间上限1.184低于非劣效界值1.214,非劣效终点达成。
  • PSA缓解率C20组29.5% vs C25组42.9%(名义P < .001),C25组更优。
  • 3/4级治疗中出现的不良事件发生率C20组39.7% vs C25组54.5%,C20组更低。

核心结论

  • 卡巴他赛在多西他赛治疗后mCRPC患者中的疗效得到确认,C20非劣效终点达成,维持了C25相对于米托蒽醌在TROPIC研究中总生存获益的≥50%。
  • 次要疗效终点更倾向于C25,C20组观察到更少的不良事件。

研究设计与样本

  • III期PROSELICA研究(ClinicalTrials.gov标识符NCT01308580),评估卡巴他赛20 mg/m2(C20)对比25 mg/m2(C25)在多西他赛治疗后mCRPC患者中的非劣效性。
  • 患者按美国东部肿瘤协作组体能状态、实体瘤疗效评价标准(RECIST)可测量性疾病和地区分层,随机分配接受C20或C25。
  • 共1200例患者随机分组(C20组598例,C25组602例),两组基线特征相似。

主要发现

  • 中位总生存C20组13.4个月 vs C25组14.5个月,HR 1.024。
  • HR置信区间上限为1.184,低于1.214非劣效界值。
  • PSA缓解率C20组29.5% vs C25组42.9%(名义P < .001),差异有利于C25。
  • 至PSA进展时间中位数C20组5.7个月 vs C25组6.8个月,C20对比C25的HR 1.195(95%CI 1.025至1.393)。
  • 健康相关生活质量两组间无差异;3/4级治疗中出现的不良事件发生率C20组39.7% vs C25组54.5%。

关键数值与推荐

  • 非劣效界值:C20对比C25的HR置信区间上限在 interim 分析后单侧98.89%CI下不得超过1.214,以95%置信水平声称C20维持C25相对于米托蒽醌在TROPIC研究中总生存获益的≥50%。
  • 实际HR置信区间上限为1.184,低于1.214非劣效界值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III TROPIC study. The phase III PROSELICA study ( ClinicalTrials.gov identifier: NCT01308580) assessed the noninferiority of cabazitaxel 20 mg/m2 (C20) versus C25 in postdocetaxel patients with mCRPC. Methods Patients were stratified by Eastern Cooperative Oncology Group performance status, measurability of disease per Response Evaluation Criteria in Solid Tumors (RECIST), and region, and randomly assigned to receive C20 or C25. To claim noninferiority of C20 (maintenance of ≥ 50% of the OS benefit of C25 v mitoxantrone in TROPIC) with 95% confidence level, the upper boundary of the CI of the hazard ratio (HR) for C20 versus C25 could not exceed 1.214 under a one-sided 98.89% CI after interim analyses. Secondary end points included progression-free survival, prostate-specific antigen (PSA), tumor and pain responses and progression, health-related quality of life, and safety. Results Overall, 1,200 patients were randomly assigned (C20, n = 598; C25, n = 602). Baseline characteristics were similar in both arms. Median OS was 13.4 months for C20 and 14.5 months for C25 (HR, 1.024). The upper boundary of the HR CI was 1.184 (less than the 1.214 noninferiority margin). Significant differences were observed in favor of C25 for PSA response (C20, 29.5%; C25, 42.9%; nominal P < .001) and time to PSA progression (median: C20, 5.7 months; C25, 6.8 months; HR for C20 v C25, 1.195; 95% CI, 1.025 to 1.393). Health-related quality of life did not differ between cohorts. Rates of grade 3 or 4 treatment-emergent adverse events were 39.7% for C20 and 54.5% for C25. Conclusion The efficacy of cabazitaxel in postdocetaxel patients with mCRPC was confirmed. The noninferiority end point was met; C20 maintained ≥ 50% of the OS benefit of C25 versus mitoxantrone in TROPIC. Secondary efficacy end points favored C25. Fewer adverse events were observed with C20.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017. PMID: 28809610. doi:10.1200/JCO.2016.72.1076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。